
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is a leading healthcare company with a positive outlook, as it has developed a groundbreaking multi-cancer early detection blood test with the potential to detect all types of cancer. The company has strong financials and a competitive advantage in the underpenetrated $100B MCED market, with a projected revenue growth of 27% and a premium multiple justified. However, the company may face risks in reduced government funding and increased regulatory hurdles, as well as dependence on volatile emerging markets.
Bears say
GRAIL is facing major obstacles in its key data presentations this month, as NHS-Galleri missed its primary endpoint and the FDA is under iterative review. Sales have shown growth, but the company may struggle with the high cost of its multi-cancer early detection test and concerns over false confidence in missing early stage cancers. Financials appear strong, but future catalysts and study results may greatly impact GRAIL's success.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares